Khoshnazar S, Mohagheghi M, Rahimi S, Dabiri S, Shahrokhi N, Shafieipour S
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39841219
DOI: 10.1007/s00210-025-03802-y.
Stone C, Ahuja G, Lopes Almeida Gomes L, Poroye J, Faden D, Xie L
JID Innov. 2024; 5(1):100311.
PMID: 39403556
PMC: 11472610.
DOI: 10.1016/j.xjidi.2024.100311.
Kim H, Werth V
Ann Dermatol. 2024; 36(5):257-265.
PMID: 39343752
PMC: 11439981.
DOI: 10.5021/ad.24.022.
Okpujie V, Ozumba S, Olaomi O, Uwumiro F, Ajiboye A, Abesin O
Cureus. 2023; 15(5):e39092.
PMID: 37378109
PMC: 10291966.
DOI: 10.7759/cureus.39092.
Aychman M, Goldman D, Kaplan J
Front Neurol. 2023; 14:1087011.
PMID: 36816569
PMC: 9932048.
DOI: 10.3389/fneur.2023.1087011.
Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.
Ramer R, Hinz B
Cells. 2022; 11(24).
PMID: 36552866
PMC: 9777118.
DOI: 10.3390/cells11244102.
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
Werth V, Hejazi E, Pena S, Haber J, Zeidi M, Reddy N
J Invest Dermatol. 2022; 142(10):2651-2659.e1.
PMID: 35490744
PMC: 10226779.
DOI: 10.1016/j.jid.2022.03.029.
COL8A1 Promotes NSCLC Progression Through IFIT1/IFIT3-Mediated EGFR Activation.
Zan X, Li S, Wei S, Gao L, Zhao L, Yan X
Front Oncol. 2022; 12:707525.
PMID: 35280763
PMC: 8907630.
DOI: 10.3389/fonc.2022.707525.
Cannabinoids for the Treatment of Dermatologic Conditions.
Sivesind T, Maghfour J, Rietcheck H, Kamel K, Malik A, Dellavalle R
JID Innov. 2022; 2(2):100095.
PMID: 35199092
PMC: 8841811.
DOI: 10.1016/j.xjidi.2022.100095.
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum.
Maddukuri S, Patel J, Diaz D, Chen K, Wysocka M, Bax C
Arthritis Res Ther. 2022; 24(1):12.
PMID: 34983619
PMC: 8725283.
DOI: 10.1186/s13075-021-02665-x.
TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease.
Maguire A, Bethea J, Kerr B
Front Neurol. 2021; 12:780876.
PMID: 34938263
PMC: 8686517.
DOI: 10.3389/fneur.2021.780876.
The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients.
Habib G, Khazin F, Artul S
Pain Res Manag. 2021; 2021:1756588.
PMID: 34531934
PMC: 8440085.
DOI: 10.1155/2021/1756588.
Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.
Scheau C, Caruntu C, Badarau I, Scheau A, Docea A, Calina D
J Pers Med. 2021; 11(6).
PMID: 34072930
PMC: 8227007.
DOI: 10.3390/jpm11060494.
Pruritus in autoimmune connective tissue diseases.
Kim H
Ann Transl Med. 2021; 9(5):441.
PMID: 33842662
PMC: 8033328.
DOI: 10.21037/atm-20-4894.
Thymoquinone reduces ischemia and reperfusion-induced intestinal injury in rats, through anti-oxidative and anti-inflammatory effects.
Parlar A, Arslan S
Turk J Surg. 2020; 36(1):96-104.
PMID: 32637881
PMC: 7315442.
DOI: 10.5578/turkjsurg.4583.
Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases.
Cintosun A, Lara-Corrales I, Pope E
Clin Drug Investig. 2020; 40(4):293-304.
PMID: 32060787
DOI: 10.1007/s40261-020-00894-7.
Cannabinoids in the Pathophysiology of Skin Inflammation.
Scheau C, Badarau I, Mihai L, Scheau A, Costache D, Constantin C
Molecules. 2020; 25(3).
PMID: 32033005
PMC: 7037408.
DOI: 10.3390/molecules25030652.
Recent Advances in Pharmacological Treatments of Adult Dermatomyositis.
Chen K, Zeidi M, Werth V
Curr Rheumatol Rep. 2019; 21(10):53.
PMID: 31473845
DOI: 10.1007/s11926-019-0850-9.
Ajulemic acid: potential treatment for chronic inflammation.
Burstein S
Pharmacol Res Perspect. 2018; 6(2):e00394.
PMID: 29638269
PMC: 5891661.
DOI: 10.1002/prp2.394.
Itch in dermatomyositis: the role of increased skin interleukin-31.
Kim H, Zeidi M, Bonciani D, Pena S, Tiao J, Sahu S
Br J Dermatol. 2018; 179(3):669-678.
PMID: 29494763
PMC: 6119520.
DOI: 10.1111/bjd.16498.